Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Ying Kiat Zee"'
Autor:
Ling-Zhi Wang, Jacqueline Ramírez, Winnie Yeo, Mei-Yi Michelle Chan, Win-Lwin Thuya, Jie-Ying Amelia Lau, Seow-Ching Wan, Andrea Li-Ann Wong, Ying-Kiat Zee, Robert Lim, Soo-Chin Lee, Paul C. Ho, How-Sung Lee, Anthony Chan, Sherry Ansher, Mark J. Ratain, Boon-Cher Goh
Publikováno v:
PLoS ONE, Vol 9, Iss 1 (2014)
Externí odkaz:
https://doaj.org/article/8a7ac3ddbc384872814137a589a51312
Autor:
Jan Wen Su, Soon Keng Goh, Ai Ching Kor, Akash Verma, Dessmon Yh. Tai, Jason D`Souza, Ying Kiat Zee, Jens Samol, Kian Chung Ong, Daniel Chan
Background: Primary lymphoepithelioma-like carcinoma (LELC) of the lung is a rare histological type of lung cancer with a relatively better prognosis. It is common in Chinese population, is associated with Epstein Barr Virus (EBV), and has morphologi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e397706104329ad61374df79ee6821e
https://doi.org/10.21203/rs.3.rs-240838/v1
https://doi.org/10.21203/rs.3.rs-240838/v1
Autor:
Ling-Zhi Wang, Jacqueline Ramírez, Winnie Yeo, Mei-Yi Michelle Chan, Win-Lwin Thuya, Jie-Ying Amelia Lau, Seow-Ching Wan, Andrea Li-Ann Wong, Ying-Kiat Zee, Robert Lim, Soo-Chin Lee, Paul C Ho, How-Sung Lee, Anthony Chan, Sherry Ansher, Mark J Ratain, Boon-Cher Goh
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e54522 (2013)
Belinostat is a hydroxamate class HDAC inhibitor that has demonstrated activity in peripheral T-cell lymphoma and is undergoing clinical trials for non-hematologic malignancies. We studied the pharmacokinetics of belinostat in hepatocellular carcinom
Externí odkaz:
https://doaj.org/article/a1e6d919d1f7484bb786a394862cf100
Autor:
Xn-Yii Lim, Wei Peng Yong, Sing-Huang Tan, Siew-Eng Lim, Ying-Kiat Zee, Soo-Chin Lee, Andrea Li Ann Wong, Nicholas Syn, Richie Soong, Marie Loh, Boon Cher Goh, Benjamin Chuah, Danny Chan, R.A. Soo, Lingzhi Wang
Publikováno v:
Scientific Reports
The FDA-approved starting dosage of capecitabine is 1,250 mg/m2, and market research indicates that U.S. physicians routinely prescribe 1,000 mg/m2. Retrospective analyses however report reduced toxicity and efficacy in a subset of patients with the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c45c3b0405ba9dcea3d8655a3a83d98
Publikováno v:
Clinical Ethics. 6:91-96
Biomedical research involving human participants is highly regulated and subject to stringent ethical requirements. Clinical research ethics, regulation and policy have tended to focus almost exclusively on the protection of participants' interests a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96bec6db90c434eef9784ee715eb1e7f
https://doi.org/10.1258/ce.2011.011019
https://doi.org/10.1258/ce.2011.011019
Autor:
Andrew R Clamp, Saran Evans, Ying Kiat Zee, Gordon C Jayson, Richard S. Welch, Claire Mitchell, Gireesh C Kumaran, Jurjees Hasan, Richard Griffiths
Publikováno v:
International Journal of Gynecologic Cancer. 21:58-65
Background:Platinum-resistant and refractory cancers of the ovary, fallopian tube, and peritoneum have a poor prognosis, yet in some cases, they can respond to multiple lines of chemotherapy. Uncertainty remains over optimal drug choice and when ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c8475f78c23dc70a3637f6a48b67299
https://doi.org/10.1097/igc.0b013e3182049273
https://doi.org/10.1097/igc.0b013e3182049273
Publikováno v:
Orbit. 31:425-427
Merkel cell carcinoma of the eyelid is a rare tumor with less than 100 reported cases worldwide. We describe an unusual presentation of Merkel cell carcinoma of the eyelid in a 60 year old Asian male. He presented with multiple left lower lid conjunc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53c209c3bc8dfcdd22ce24c3e9774d07
https://doi.org/10.3109/01676830.2012.689084
https://doi.org/10.3109/01676830.2012.689084
Autor:
Ling-Zhi Wang, Jacqueline RamÃrez, Winnie Yeo, Mei-Yi Michelle Chan, Win-Lwin Thuya, Jie-Ying Amelia Lau, Seow-Ching Wan, Andrea Li-Ann Wong, Ying-Kiat Zee, Robert Lim, Soo-Chin Lee, Paul C. Ho, How-Sung Lee, Anthony Chan, Sherry Ansher, Mark J. Ratain, Boon-Cher Goh
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 1 (2014)
PLoS ONE, Vol 9, Iss 1 (2014)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::291d4f1649cb46962fa45221b4e9fc30
http://europepmc.org/articles/PMC3890364
http://europepmc.org/articles/PMC3890364
Autor:
Andrew R Clamp, Gordon C Jayson, Leila Khoja, Ric Swindell, Jurjees Hasan, Gireesh C Kumaran, Nishanth Murukesh, Gregory Wilson, Ying-Kiat Zee, Mark P Saunders, Juan W. Valle
Publikováno v:
Journal of clinical gastroenterology. 48(5)
BACKGROUND:: The vascular endothelial growth factor pathway is strongly implicated in cancer-related angiogenesis. Antiangiogenic agents such as bevacizumab commonly cause hypertension (HTN) and proteinuria (PTN), which may be biomarkers of response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b730faae183cc56ce291888d63bc801
https://pubmed.ncbi.nlm.nih.gov/24153157
https://pubmed.ncbi.nlm.nih.gov/24153157
Autor:
Sherry Ansher, How Sung Lee, Mei Yi Michelle Chan, Anthony T.C. Chan, Soo-Chin Lee, Ying Kiat Zee, Winnie Yeo, Win Lwin Thuya, Robert Lim, Seow Ching Wan, Mark J. Ratain, Paul C. Ho, Andrea Li Ann Wong, Lingzhi Wang, Jacqueline Ramírez, Jie Ying Amelia Lau, Boon Cher Goh
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 1, p e54522 (2013)
PLoS ONE, Vol 8, Iss 1, p e54522 (2013)
Belinostat is a hydroxamate class HDAC inhibitor that has demonstrated activity in peripheral T-cell lymphoma and is undergoing clinical trials for non-hematologic malignancies. We studied the pharmacokinetics of belinostat in hepatocellular carcinom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18ba33513e0e1e87579bad3ebb033d37
http://europepmc.org/articles/PMC3559838
http://europepmc.org/articles/PMC3559838